Purevax RCCh
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
Table of contents
Overview
The marketing authorisation for Purevax RCCh has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Authorisation details
| Product details | |
|---|---|
| Name |
Purevax RCCh
|
| Agency product number |
EMEA/V/C/000092
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
|
| Species |
Cats
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AH
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
22/02/2005
|
| Contact address |
29 Avenue Tony Garnier |
Product information
12/02/2014 Purevax RCCh - EMEA/V/C/000092 - R/0007
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for felidae
Therapeutic indication
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs;
- against calicivirus infection to reduce clinical signs and excretion;
- against Chlamydophila felis infection to reduce clinical signs.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.
The duration of immunity is 1 year after the last (re-)vaccination.